Luye Pharma Group held a launch conference on March 27, 2021 to officially announce the launch of a new drug Rykindo® (Risperidone Microspheres for Injection (II)) in China.Rykindo® is an extended rel...
Luye Pharma Group today announced that the Group’s Class 1 new chemical entity (NCE) product Anshufaxine Hydrochloride Extended-Release Tablets (LY03005) has met the predefined endpoints in a ph...
Luye Pharma Group announced today that China’s National Medical Products Administration (NMPA) has approved the company’s independently developed Risperidone Microspheres for Injection (II...
Lung cancer is the malignancy with the highest morbidity and mortality worldwide. As one of the common histological types of Non-Small-Cell Lung Cancer (NSCLC), the treatment of advanced squamous cell...
Luye Pharma Group announced today that the enrollment and follow-up of patients in a phase III clinical trial, an efficacy and safety comparative study of LY03005 with placebo, has been completed in r...
Luye Pharma Group announced today that one of its key central nervous system (CNS) products, Rivastigmine Transdermal Patch, has been approved by the National Medical Products Administration in China....
-Luye Pharma grants Distriphil exclusive distribution and marketing rights for Seroquel® and Seroquel XR® in the Philippines- Two companies pledge to make joint effort to raise awareness of mental hea...
Luye Pharma Group recently signed two agreements with partners in Latin America, boosting further development of the central nervous system (CNS) drugs Seroquel® (quetiapine fumarate, immediate releas...
Shanghai, September 11, 2020–The Shanghai Mental Health Center (SMHC) and Mindfront Health, a subsidiary of Luye Life Sciences Group, entered into a strategic partnership today. The two parties ...
Luye Pharma Group announced today that the company has received the approval from the Center for Drug Evaluation of China to begin clinical trials for the new drug product Rivastigmine Multi-Day Trans...
TOP